SPH4336 + cadonilimab

SPH4336 + cadonilimab is an investigational **combination therapy** of two agents for cancer. **SPH4336** is a novel, highly selective, oral small molecule inhibitor targeting cyclin-dependent kinase 4 and 6 (CDK4/6). It demonstrates anti-tumor activity by inhibiting cell cycle progression in tumor cells, notably showing potential in breast cancer and sarcoma[1][3]. **Cadonilimab** (AK104) is a tetravalent bispecific monoclonal antibody that targets both programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), effectively blocking immune checkpoint pathways, activating T cells, and promoting anti-tumor immunity with reduced toxicity compared to separate PD-1 and CTLA-4 blockade[2]. The combination leverages cell cycle arrest (by SPH4336) and enhanced immune response (by cadonilimab) for potential synergistic anti-cancer effect.

Other names

cadonilimab